Veracyte, Inc.
VCYT
|
News
|
$19.92
0.45%
0.45%
500K
|
Health Technology
(0.0% 1d) (-5.6% 1m) (-10.2% 1y) (0.0% 2d) (-0.1% 3d) (3.3% 7d) (-12.58% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 1,495,351,034
http://www.veracyte.com
Sec Filling | Patents | 354 employees
(US) Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
cancer lung cancer fibrosis lungs diagnostics
add to watch list Paper trade email alert is off
Press-releases
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
Published: 2024-04-22 (Crawled : 23:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 1.03%
H: 2.65%
C: 1.02%
first financial results
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Published: 2024-04-22 (Crawled : 17:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 1.03%
H: 2.65%
C: 1.02%
active test cancer for study
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: -1.41%
bladder
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Published: 2024-02-27 (Crawled : 00:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 0.68%
H: 0.34%
C: -0.42%
guidelines test cancer molecular
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Published: 2024-02-21 (Crawled : 00:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: -0.8%
H: 0.93%
C: -1.17%
conference
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Published: 2024-02-08 (Crawled : 00:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 0.33%
H: 2.82%
C: 2.29%
financial results
Veracyte Completes Acquisition of C2i Genomics
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 0.45%
H: 7.5%
C: 3.33%
genomics acquisition
World Molecular Diagnostics Market Research Report 2023-2028 - Companion Diagnostics and Molecular Pharmacokinetics Revolutionizes Drug Therapies
Published: 2024-01-19 (Crawled : 01:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
BIO | $278.21 -2.48% 0.0% 210K
|
Health Technology
|
| O: 0.14%
H: 1.0%
C: 0.68%
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 0.12%
H: 0.35%
C: -0.2%
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
MYGN | $18.61 0.05% 0.05% 480K
|
Health Technology
|
| O: 1.04%
H: 0.49%
C: -0.49%
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: -0.18%
H: 2.05%
C: 1.4%
HOLX | $76.71 -0.62% -0.63% 910K
|
Health Technology
|
| O: 0.29%
H: 0.07%
C: -0.33%
CDNA | $7.995 -2.86% -2.94% 520K
|
Health Technology
|
| O: 0.62%
H: 0.51%
C: -4.74%
drug report world research companion diagnostics molecular market
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Published: 2024-01-08 (Crawled : 18:00) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.03%
H: 0.67%
C: 0.32%
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: 2.53%
H: 10.54%
C: 10.31%
disease genomics acquisition diagnostics platform
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Published: 2023-12-01 (Crawled : 23:00) - biospace.com/
VCYT | News | $19.92 0.45% 0.45% 500K
|
Health Technology
|
| O: -0.51%
H: 4.28%
C: 4.2%
genomic cancer show
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
TGEN P 16000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
WABC | $47.86 0.21% 0.21% 140K
|
Finance
|
19:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
17:00
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
TPL P 3 | $589.01 0.2% -0.04% 53K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 1.63% 3.1K
|
Finance and Insurance
|
15:01
MEGI | $12.04 0.5% 0.0% 150K
|
|
00:30
CTRN P 29000 | $22.11 -0.54% -0.54% 65K
|
Retail Trade
|
22:00
CONN | $3.78 2.16% 2.12% 36K
|
Retail Trade
|
21:30
CMTV P 700 | $16.59 17.43% 1K
|
Finance and Insurance
|
18:30
FNB | $13.67 0.29% 0.0% 2.2M
|
Finance
|
17:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10